Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
about
Antibodies to watch in 2017Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.The role of IL-6 in host defence against infections: immunobiology and clinical implications.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Sarilumab: First Global Approval.The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.Treatment with Biologicals in Rheumatoid Arthritis: An Overview.Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis.Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritisReview of Biosimilar Trials and Data on Adalimumab in Rheumatoid ArthritisEfficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic ReviewSarilumab: patient-reported outcomes in rheumatoid arthritis
P2860
Q37631319-7F1112AC-F8F2-4032-A0BA-A581B715BA35Q38660813-D0F24C65-5A1E-4715-9F11-3FD0078D8CB7Q38685086-5BE3F3F9-AA38-465C-8ABC-B003A41CB780Q38725223-0B262D2C-D3CB-4B9A-BFF3-E72D86D2934BQ38745066-14F54345-7D28-4998-AEBC-27549B93A25FQ39177162-7BF9480A-E663-4D9A-BC62-239D40341B30Q39215645-58CDAB42-E1E0-4753-8AC4-C1A147FD48C3Q47131401-18BF613E-C589-4C9B-AFA4-590817CE5C61Q47132835-FA2189EE-775C-404E-BEBA-47078F19221BQ47325125-0FFBE02D-B47C-48DC-BB7B-BB9B6B761590Q47692825-75144338-01DD-4AF2-9D0F-D20D490FCE9DQ50334739-F9819EE2-1C32-47FC-95BA-1888094CE0E0Q52675492-CAE35037-338F-4A6F-8D08-3CA189C712A2Q55360477-502E855C-CC4D-4C57-8C41-E7A1FF2CE1B2Q57330076-9B587BCC-4ADB-41A9-A856-E9591CB8E0A8Q57741141-0A6D2AC4-5279-43C1-B957-22BED2A61F59Q58732393-6654A795-022B-422B-BAF4-868DEA477446Q58735831-69C23D46-2A85-4E25-A191-25A7ECE8D83E
P2860
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Efficacy and safety of sarilum ...... arallel-group phase III trial.
@en
type
label
Efficacy and safety of sarilum ...... arallel-group phase III trial.
@en
prefLabel
Efficacy and safety of sarilum ...... arallel-group phase III trial.
@en
P2093
P2860
P1476
Efficacy and safety of sarilum ...... arallel-group phase III trial.
@en
P2093
Deborah Bauer
Erin K Mangan
Eun Bong Lee
Hubert van Hoogstraten
Janet van Adelsberg
Juan Ignacio Vargas
Neil M H Graham
Rahul Patel
P2860
P304
P356
10.1136/ANNRHEUMDIS-2016-210310
P407
P577
2016-11-17T00:00:00Z